You must develop a point-of-care diagnostic test that can rule out antibiotic use or help identify an effective antibiotic to treat a patient.
Collaborations from various fields of science, technology and business are welcomed and encouraged. The team must be able to demonstrate that in winning the prize it would deliver direct economic growth or benefit or social benefit in the United Kingdom (UK).
The winning solution must advance Nesta’s Charitable Objects for public benefit.
To demonstrate such benefit the team must:
Include a member which has a presence in the United Kingdom, meaning an office in the UK, affiliation with a UK company or partnership with a UK organisation or institution, and meet one of the following requirements:
- carry out manufacturing and/or design of the winning solution in the UK, or
- lab test or showcase the winning solutions in the UK, or
- use some other means agreed in writing with Nesta and Innovate UK before participating in the Longitude Prize.
Eligibility Criteria - Checklist
The Longitude Prize will reward a competitor that can develop a transformative point-of-care diagnostic test that will conserve antibiotics for future generations and revolutionise the delivery of global healthcare. The test must be accurate, rapid, affordable, easy-to-use and available to anyone, anywhere in the world.
The test must be accurate enough to eliminate harmful treatment decisions, inform more targeted antibiotic use, and give users, e.g. patients, health workers, the confidence to act upon its result.
At forecasted full scale manufacture the test, including any instrumentation, must be affordable for purchase and use in its intended global market(s). Less expensive tests will be favoured. Please provide evidence of affordability in each multiple applicable markets.
The time from sample collection to reporting of the result to the treatment decision–maker must be less than thirty minutes. More rapid tests will be favoured.
Globally applicable – the test must be suitable for point–of–care use in as many global healthcare settings where the test could be used toinform treatment decisions as possible.
Minimally reliant on healthcare resources – the test must require minimal healthcare resources and training to be used effectively and
Easy–to–use and interpret – the test must be easy to use and interpret safely and effectively, in the global settings and locations where it
will be used. Please provide evidence to support your claim that the relevant user of the test would be able to use it effectively. Please
consider issues of language and literacy.
Ready for manufacture and distribution – there must be a feasible product commercialisation plan for full–scale manufacture and global
Original – you must take reasonable steps to find out whether your technology infringes on the intellectual property rights of others.
The risks associated with a test will be judged against the benefit it can provide. Please tell us the main risks associated with your test and
how you would address each of these.
Tests which have an in–built data recording and transmitting capacity will be favoured. A test does not need to have this capacity in order
to win the prize.